Guidance Quotations

With the rule changes that the league has adopted for the upcoming season, we believe that Stephen is ideally suited to provide direction and guidance to our on-ice officials. His judgment and professionalism on the ice, coupled with the respect he has earned as one of the top officials in the game, will be of great benefit in his transition to the officiating management ranks.

But the shares could well be valued well above this, based on increasing visible earnings strength, ... Cypress closed the June quarter with strong bookings growth, in excess of earlier guidance of $360 million, possibly as high as $400 million and experienced strong sequential revenue growth with sharply higher gross margins.

But there is a concern that GPSS, which is the largest government agency, doesn't have the guidance of a chief financial officer. They need someone to do that sort of financial management and planning to prepare for situations like this month's three pay periods.

Business conditions continue to be robust. The company expressed high confidence in its third-quarter guidance of greater than $3 billion in bookings, $2.6 to $2.7 million in revenue and EPS of 64 to 68 cents. We believe guidance is conservative and estimate bookings of $3.3 billion with EPS of 70 cents, versus the Street consensus of 68 cents a share.

We feel that our data are completely consistent with the current American Heart Association guidelines and the current FDA guidance to use the lowest possible dose for the shortest possible duration.

We're experiencing a wait-and-see attitude because it's widely expected that earnings will not be that great. The odd surprise will help bolster the market but more importantly investors are waiting to hear guidance heading into the next quarter.

We're just in some hot areas right now that are driving a lot of strength. We're not dependent on an exceptionally strong September to deliver the guidance we just gave.

One of the biggest barriers research and academic institutions face is the ability to get discoveries made in the lab into clinical testing. The new Exploratory IND guidance emphasizes the flexibility available to researchers when conducting early clinical testing of these cutting-edge treatments. As we enter the era of personalized medicine, these exploratory approaches enable scientists to take full advantage of new technologies to target the development of more individualized therapies.

I think investors will be happy with that guidance.

I think investors are really pleased with what they heard about the future guidance for the second half. We think that the second half will indeed turn out to be better for Intel. It's seasonally stronger for them. At the same time, they're doing an excellent job reducing their cost.